







an Open Access Journal by MDPI

Marine Drugs in Clinical Trials

Guest Editor:

Dr. David J. Newman

Retired Branch Chief, Natural Products Branch, National Cancer Institute, Frederick, MD 21702-1201, USA

Deadline for manuscript submissions:

closed (15 February 2018)

Message from the Guest Editor

Dear Colleagues,

The aim of this Special Issue is to demonstrate the utility of marine-sourced materials (from invertebrates, microbes of all types, and micro- and macro-algae as sources of such agents). Compounds should have reached the preclinical stage and be candidates for clinical trials in humans, though, depending on their source, agents at the preclinical stage can be considered on their merits.

Dr. David John Newman Guest Editor













an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Bill J. Baker

Department of Chemistry, University of South Florida, 4202 E. Fowler Ave., CHE 205, Tampa, FL 33620-5250, USA

Message from the Editor-in-Chief

During the past few decades there has been an ever increasing number of novel compounds discovered in the marine environment. This is exemplified by the robust preclinical and clinical pipeline that currently exists for marine natural products. *Marine Drugs* is inviting contributions on new advances in marine biotechnology, pharmacology, chemical ecology, synthetic biology, and genomics approaches related to the discovery of therapeutically relevant marine natural products. Our goal is to share your contribution in a timely fashion and in a manner that will be valued by the scientific community.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, MarinLit, AGRIS, and other databases.

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q1 (*Pharmacology, Toxicology and Pharmaceutics (miscellaneous)*)

Contact Us